These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22248199)

  • 1. Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats.
    Koçak G; Azak A; Astarcı HM; Huddam B; Karaca G; Ceri M; Can M; Sert M; Duranay M
    Ther Apher Dial; 2012 Feb; 16(1):75-80. PubMed ID: 22248199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
    Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
    Crespo MJ; Cangiano JL; Altieri PI; Escobales N
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
    Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
    Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
    J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis.
    Bozkurt D; Cetin P; Sipahi S; Hur E; Nar H; Ertilav M; Sezak M; Duman S
    Perit Dial Int; 2008 Nov; 28 Suppl 5():S38-42. PubMed ID: 19008539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
    Chrysant SG
    Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
    Imanishi T; Tsujioka H; Ikejima H; Kuroi A; Takarada S; Kitabata H; Tanimoto T; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of the renin system by aliskiren and valsartan.
    Birkenhäger WH; Staessen JA
    Lancet; 2007 Jul; 370(9583):195-196. PubMed ID: 17658374
    [No Abstract]   [Full Text] [Related]  

  • 14. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.
    Whaley-Connell A; Habibi J; Nistala R; Hayden MR; Pulakat L; Sinak C; Locher B; Ferrario CM; Sowers JR
    Regul Pept; 2012 Jun; 176(1-3):36-44. PubMed ID: 22465166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
    Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
    J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS; Ziogas J; Campbell DJ
    Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
    Whaley-Connell A; Habibi J; Rehmer N; Ardhanari S; Hayden MR; Pulakat L; Krueger C; Ferrario CM; DeMarco VG; Sowers JR
    Metabolism; 2013 Jun; 62(6):861-72. PubMed ID: 23352204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
    Pilz B; Shagdarsuren E; Wellner M; Fiebeler A; Dechend R; Gratze P; Meiners S; Feldman DL; Webb RL; Garrelds IM; Jan Danser AH; Luft FC; Müller DN
    Hypertension; 2005 Sep; 46(3):569-76. PubMed ID: 16103264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.